ArticleChinese journal of integrative medicine2026
Compound Kushen Injection Alleviates Experimental Colitis in Mice by Regulating Macrophage Polarization through TLR4/NF-κB Signaling.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the therapeutic effect and mechanism of Compound Kushen Injection (CKI) in dextran sulfate sodium (DSS)-induced ulcerative colitis (UC).
methodsNetwork pharmacology was used to predict the potential targets and pathways for CKI's therapeutic effects on UC. Thirty-five male C57BL/6 mice were randomized into 5 groups, including control, DSS model, 5-aminosalicylic acid (5-ASA), low- and high-dose CKI groups (n=7 per group). A 7-d protocol of ad libitum administration of 3% (w/v) DSS in drinking water was implemented to induce experimental colitis in mice of all groups except the control. Mice received daily intragastric 5-ASA (50 mg/kg), low-dose (2 mL/kg) or high-dose (4 mL/kg) CKI accordingly. In vivo therapeutic effects of CKI were evaluated via histology, ELISA and immunohistochemistry. In vitro, LPS-stimulated RAW264.7 inflammatory cells were treated with CKI for 24 h to detect cytokine changes. Immunofluorescence, flow cytometry and Western blot were applied to analyze macrophage polarization phenotypes in mouse peritoneal macrophages and RAW264.7 cells.
resultsNetwork pharmacology analysis indicated that CKI's therapeutic effects on UC involved macrophage polarization regulation. CKI substantially alleviated DSS-induced colitis symptoms, improved intestinal barrier function, and reduced both pro-inflammatory cytokine secretion and oxidative stress in colonic tissues (P<0.05 or P<0.01). Upon DSS or LPS stimulation, CKI treatment markedly decreased M1 macrophage marker expression and increased M2 markers (P<0.05 or P<0.01). Mechanistic studies further revealed that CKI modulated macrophage polarization via Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) signaling pathway (P<0.05 or P<0.01).
conclusionsCKI alleviates experimental colitis in mice by modulating macrophage polarization, reducing inflammatory responses, and repairing the intestinal barrier; this effect may closely associated with inhibition of TLR4/NF-κB signaling pathway.
Indexed as
Identifiers
42771292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.